Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjects.

Pene Dumitrescu, T; Anic-Milic, T; Oreskovic, K; Padovan, J; Brouwer, K L R; Zuo, P; Schmith, V D

Pene Dumitrescu, T; Anic-Milic, T; Oreskovic, K; Padovan, J; Brouwer, K L R; Zuo, P; Schmith, V D.

Affiliation

Pene Dumitrescu T; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. teodora.x.pene-dumitrescu@gsk.com

Antimicrob Agents Chemother ; 57(7): 3194-201, 2013 Jul.

Article in En | MEDLINE | ID: mdl-23629714

Subject(s)

Anti-Bacterial Agents/blood; Azithromycin/blood; Administration, Oral; Adult; Half-Life; Humans; Leukocytes, Mononuclear/drug effects; Male; Middle Aged; Neutrophils/drug effects; Plasma; Young Adult

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Azithromycin / Anti-Bacterial Agents Type of study: Prognostic_studies Limits: Adult / Humans / Male / Middle aged Language: En Journal: Antimicrob Agents Chemother Year: 2013 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google